23938-73-0

Basic information

• Product Name: 2-Amino-3-methoxy-4-(phenylmethoxy)benzoic acid
• Synonyms: 2-Amino-3-methoxy-4-(phenylmethoxy)benzoic acid;4-(Benzyloxy)-3-methoxyanthranilic acid;2-aMino-4-(benzyloxy)-3-Methoxybenzoic acid;2-Amino-4-(benzyloxy)
• CAS NO: 23938-73-0
• Molecular Formula: C₁₅H₁₅NO₄
• Molecular Weight: 273.2839
• Mol File: 23938-73-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.283
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 2-Amino-3-methoxy-4-(phenylmethoxy)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-3-methoxy-4-(phenylmethoxy)benzoic acid(23938-73-0)
• EPA Substance Registry System: 2-Amino-3-methoxy-4-(phenylmethoxy)benzoic acid(23938-73-0)

Safety Data

• Hazardous Substances Data: 23938-73-0(Hazardous Substances Data)

Usage

General Description

"2-Amino-3-methoxy-4-(phenylmethoxy)benzoic acid" is a chemical compound that belongs to the class of amino acids. It has a molecular formula C15H15NO4 and a molecular weight of 273.28 g/mol. 2-Amino-3-methoxy-4-(phenylmethoxy)benzoic acid is also known by the name of Mocetinostat, and it is widely used in the field of pharmaceuticals. Mocetinostat is a histone deacetylase inhibitor, which means it has the ability to modify the structure of chromatin and alter gene expression. This property makes it a potential candidate for the treatment of various cancers and other diseases related to epigenetic dysregulation. Additionally, it is also being studied for its potential in the treatment of neurodegenerative diseases.

Upstream product

• 3584-32-5 4-(benzyloxy)-3-methoxy-2-nitrobenzoic acid 

Downstream Products

• 31236-20-1 7-benzyloxy-8-methoxy-2-methyl-benzo[d][1,3]oxazin-4-one 
• 135082-42-7 4-(benzyloxy)-3-methoxy-N-(2,3,4,5-tetramethoxyphenyl)anthranilic acid 
• 82354-35-6 des-N-methylnoracronycine 
• 135082-47-2 6-(benzyloxy)-1-hydroxy-10-methyl-2,3,4,5-tetramethoxyacridin-9-one 
• 135082-45-0 6-(benzyloxy)-1,2,3,4,5-pentamethoxyacridin-9-one 
• 135082-46-1 6-(benzyloxy)-10-methyl-1,2,3,4,5-pentamethoxyacridin-9-one 
• 142003-89-2 6-(benzyloxy)-3,4-dimethoxy-10-methylacridine-1,2,9-trione 
• 142003-88-1 6-(benzyloxy)-2,3-dimethoxy-10-methylacridine-1,4,9-trione 
• 142003-86-9 6-(benzyloxy)-10-<2-(diethylamino)ethyl>-1,2,3,4,5-pentamethoxyacridin-9-one 
• 142003-90-5 3-(benzyloxy)-5-methyl-4,6,7-trimethoxyquino<3,2-a>phenazin-14(5H)-one 
• 1325207-38-2 4-benzyloxy-2-iodo-3-methoxybenzoic acid 
• 1325207-40-6 4-benzyloxy-3-methoxy-2-(3,4,5-trimethoxyphenylamino)benzoic acid 
• 1325207-42-8 6-benzyloxy-1,2,3,5-tetramethoxy-10H-acridin-9-one 
• 1325207-76-8 (E)-3-(6-benzyloxy-1,2,3,5-tetramethoxy-9-oxo-9H-acridin-10-yl)acrylic acid 

Relevant articles and documents

Multisubstituted 1-hydroxy-9-acridones with anticancer activity

The present invention provides a compound having the structure: STR1 The present invention also provides a method for synthesizing a compound having the above-identified structure as well as the intermediate compounds produced according to that method. The present invention further provides a pharmaceutical composition comprising the above compounds. Lastly, the present invention provides a method of inhibiting growth of tumor cells.

SYNTHESIS OF GLYFOLINE, A CONSTITUENT OF GLYCOSMIS CITRIFOLIA (WILLD.) LINDL. AND A POTENTIAL ANTICANCER AGENT

Condensation of 4-benzyloxy-3-methoxyanthranilic acid (3) with 5-iodo-1,2,3,4-tetramethoxybenzene (4) gave 6-benzyloxy-1,2,3,4,5-pentamethoxy-9-acridone (7), which was then converted into glyfoline (1) via N-methylation, selective de-O-methylation, and de